Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms

AbstractTakotsubo syndrome (TTS) is an acute heart failure syndrome with significant rates of in and out-of-hospital mayor cardiac adverse events (MACE). To evaluate the possible role of neoplastic biomarkers [CA-15.3, CA-19.9 and Carcinoembryonic Antigen (CEA)] as prognostic marker at short- and long-term follow-up in subjects with TTS. Ninety consecutive subjects with TTS were enrolled and followed for a median of 3 years. Circulating levels of CA-15.3, CA-19.9 and CEA were evaluated at admission, after 72 h and at discharge. Incidence of MACE during hospitalization and follow-up were recorded. Forty-three (46%) patients experienced MACE during hospitalization. These patients had increased admission levels of CEA (4.3 ± 6.2 vs. 2.2 ± 1.5 ng/mL, p = 0.03). CEA levels were higher in subjects with in-hospital MACE. At long term follow-up, CEA and CA-19.9 levels were associated with increased risk of death (log rank p < 0.01, HR = 5.3, 95% CI 1.9–14.8, HR = 7.8 95% CI 2.4–25.1, respectively, p < 0.01). At multivariable analysis levels higher than median of CEA, CA-19.9 or both were independent predictors of death at long term (Log-Rank p < 0.01). Having both CEA and CA-19.9 levels above median (> 2 ng/mL, > 8 UI/mL respectively) was associated with an increased risk of mortality of 11.8 (95% CI 2.6–52.5, p = 0.001) at follow up. Increased CEA and CA-19.9 serum levels are associated with higher risk of death at long-term follow up in patients with TTS. CEA serum levels are correlated with in-hospital MACE.

Download Full-text

Analytical Performance of Ca 19.9, Ca 125 and Ca 15.3 Assays as Observed through an External Quality Assessment Program

The International Journal of Biological Markers ◽

10.1177/172460089400900109 ◽

1994 ◽

Vol 9 (1) ◽

pp. 43-47 ◽

Cited By ~ 5

Author(s):

G.C. Zucchelli ◽

A. Pilo ◽

M.R. Chiesa ◽

S. Masini ◽

A. Clerico

Keyword(s):

Monoclonal Antibody ◽

Quality Control ◽

Quality Assessment ◽

External Quality Assessment ◽

Ca 125 ◽

External Quality ◽

Ca 15.3 ◽

Assessment Program ◽

Ca 19.9 ◽

Control Samples

Immunoassays of the tumor markers CA 19.9, CA125 and CA 15.3 are generally acknowledged to be a useful tool in the management of cancer patients. As a consequence, many methods developed by different companies are now commercially available. However, discrepancies have been described in the results of marker determinations even when the same monoclonal antibody was used. An external quality assessment (EQA) was carried out; starting from 1989 about 110 laboratories participated; since December 1991 the program was linked with the interlaboratory program Oncocheck organized by the Service de Radiopharmacie et Radioanalyse, University of Lyon. At present more than 200 laboratories of many European countries are involved: cumulatively 47 quality control samples have been prepared and sent to the participants. This manuscript is a report on data collected for CA 19.9, CA 125, and CA 15.3.

Download Full-text

Stability of Tumor Markers CA 19.9, CA 125, and CA 15.3 in Serum Obtained from Plain Tubes and Tubes Containing Thixotropic Gel Separator

Clinical Chemistry ◽

10.1093/clinchem/43.12.2430 ◽

1997 ◽

Vol 43 (12) ◽

pp. 2430-2431 ◽

Cited By ~ 6

Author(s):

Giuseppe Banfi ◽

Pierangela Parma ◽

Marina Pontillo

Keyword(s):

Tumor Markers ◽

Ca 125 ◽

Ca 15.3 ◽

Ca 19.9

Download Full-text

Serum Tumor Markers may Precede Instrumental Response to Chemotherapy in Patients with Metastatic Cancer

The International Journal of Biological Markers ◽

10.1177/172460080301800408 ◽

2003 ◽

Vol 18 (4) ◽

pp. 295-300 ◽

Cited By ~ 7

Author(s):

C. Massacesi ◽

M.B.L. Rocchi ◽

F. Marcucci ◽

A. Pilone ◽

M. Galeazzi ◽

...

Keyword(s):

Cancer Patients ◽

Tumor Markers ◽

Clinical Benefit ◽

Instrumental Response ◽

Metastatic Cancer ◽

Ca 125 ◽

Ca 15.3 ◽

Serum Tumor Markers ◽

Ca 19.9 ◽

Pain Improvement

Purpose Although serum tumor markers (STMs) are widely used in clinical practice, their predictive role for the response to anticancer treatment is still controversial. The correlation of CEA, CA 15.3, CA 19.9, CA 125 (only with peritoneal involvement) and NSE levels with imaging response and clinical benefit was investigated in 60 non-selected patients with metastatic epithelial cancers treated by single-agent docetaxel chemotherapy. Methods STM measurement was performed at baseline and subsequently every three to four weeks. We applied the WHO criteria to evaluate both STM and instrumental responses. Concordance analysis was performed by the Cohen Kw index, and the significance of the results was established using the Fleiss, Cohen & Everitt test. Qualitative interpretation of data was obtained with the Landis & Koch scale. Correlations of STM response with clinical benefit (PS or pain improvement) were evaluated by the chi-square test. Results The primary tumors included breast cancers (38 patients), gastrointestinal non-colorectal cancers (12 patients), and lung cancers (10 patients). An overall significant good degree of agreement was observed between STM and instrumental response (p<0.0005). The degree of agreement for each marker was as follows: excellent for CEA (p<0.0005) and CA 125 (p=0.006), good for CA 15.3 (p<0.0005) and CA 19.9 (p=0.011). Restricted analysis for the correlation of each marker with primary tumor origin showed good prediction of radiological response for CA 15.3 and CEA in breast cancer patients (p<0.0005 for both), for CEA and CA 19.9 in gastrointestinal cancer patients (p=0.01 and 0.04, respectively), and for CEA+NSE in lung cancer patients (p=0.01). Conversely, STM response did not correlate significantly with the clinical benefit for the patients, both in terms of PS and pain improvement (p=0.24 and p=0.42, respectively). Conclusion This study showed STMs to be good predictors of tumor response. Although STMs cannot replace diagnostic imaging, in metastatic cancer they might be useful to optimize the timing of radiological re-evaluation in the palliative setting.

Download Full-text

Dosage des marqueurs tumoraux ACE, CA 15.3, CA 125 et CA 19.9 dans les liquides dˈépanchement et le LCR par immunoanalyse en phase homogène. Corrélation avec les résultats cytologiques et les concentrations sériques

Immuno-analyse & Biologie Spécialisée ◽

10.1016/s0923-2532(02)01162-6 ◽

2002 ◽

Vol 17 (1) ◽

pp. 18-25 ◽

Cited By ~ 2

Author(s):

S Guepratte ◽

C Pallud ◽

M.F Pichon

Keyword(s):

Ca 125 ◽

Ca 15.3 ◽

Ca 19.9 ◽

Marqueurs Tumoraux

Download Full-text

Valor diagnóstico de la combinación de nueve marcadores tumorales en neoplasias

QhaliKay Revista de Ciencias de la Salud ISSN 2588-0608 ◽

10.33936/qkrcs.v1i1.123 ◽

2017 ◽

Vol 1 (1) ◽

pp. 19

Author(s):

Ivón Howland Álvarez ◽

Yolanda Cruz Gómez ◽

Nairobi Fonseca Torres ◽

Bárbara Dinorah Hidalgo Martínez ◽

Viorkis Pérez Ortiz ◽

...

Keyword(s):

Tumor Markers ◽

Predictive Value ◽

Clinical Laboratory ◽

Reference Value ◽

Ca 125 ◽

Cytokeratin 19 ◽

Neoplastic Disease ◽

Ca 15.3 ◽

Ca 19.9 ◽

Marcadores Tumorales

Muchos marcadores tumorales (MT) no son específicos a un tipo particular de cáncer y el nivel de uno de ellos puede aumentar como consecuencia de más de un tipo de cáncer, por lo que se utilizan en combinación para lograr mayor efectividad diagnóstica. Este trabajo se propone evaluar el valor diagnóstico de la combinación de nueve MT utilizados en diagnóstico de neoplasia tanto de forma individual como combinados. Se realizó un estudio retrospectivo entre enero 2013 y mayo de 2015 en el Laboratorio Clínico del Centro de Investigaciones Médico Quirúrgicas de La Habana a 100 pacientes con diagnóstico de cáncer o sospecha clínica de neoplasia oculta a quienes se les determinaron los marcadores tumorales: antígeno carbohidrato (CA) 19.9, CA 72.4, CA 125, CA 15.3, antígeno carcinoembrionario (CEA), componente de la citoqueratina 19 (Cyfra 21-1), gonadotropina coriónica (HCG), ferritina y antígeno prostático de superficie (PSA). En todos los MT se observó un incremento del valor de corte sobre el valor límite superior de referencia mayor al 8%. En conjunto, la sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo fueron de 23%, 99%, 96% y 51%, respectivamente. Para un valor de corte de 50 la especificidad y el VPP aumentaron a 99,6% y 97,5%, respectivamente. El uso de los 9 marcadores tumorales en conjunto mostró ser útil en el proceso de diagnóstico de pacientes con enfermedad neoplásica. Palabras clave: marcadores tumorales, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina y PSA Abstract: Many tumor markers are not specific to a particular type of cancer and the level of one of them may increase as a result of more than one type of cancer, that’s why they are used in combination to achieve greater diagnostic effectiveness. This work aims to evaluate the diagnostic value of the combination of nine tumor markers commonly used in diagnosis of neoplasia both individually and in combination. A retrospective study from January 2013 to May 2015 was conducted at the Clinical Laboratory of the Center for Medical and Surgical Research in Havana, in 100 patients with cancer diagnosis or clinical suspicion of occult malignancy and to whom carbohydrate antigen (CA) 19.9, 72.4, CA 125, CA 15.3, carcinoembryonic antigen (CEA), component cytokeratin 19 (CYFRA 21-1), chorionic gonadotropin (HCG), ferritin and prostate surface antigen (PSA) tumor markers were identified. An increase of cutoff value above the upper limit reference value in all higher TM 8% was observed. Overall, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value were 23 %, 99 %, 96 % and 51 %, respectively. For a cut value of 50 specificity and PPV, they increased to 99.6% and 97.5%, respectively. The use of 9 tumor markers together showed to be useful in the process of diagnosing patients with neoplastic disease. Key words: tumor markers, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina and PSA.

Download Full-text

Valor diagnóstico de la combinación de nueve marcadores tumorales en neoplasias

QhaliKay Revista de Ciencias de la Salud ISSN 2588-0608 ◽

10.33936/qhalikay.v1i1.123 ◽

2017 ◽

Vol 1 (1) ◽

pp. 19

Author(s):

Ivón Howland Álvarez ◽

Yolanda Cruz Gómez ◽

Nairobi Fonseca Torres ◽

Bárbara Dinorah Hidalgo Martínez ◽

Viorkis Pérez Ortiz ◽

...

Keyword(s):

Tumor Markers ◽

Predictive Value ◽

Clinical Laboratory ◽

Reference Value ◽

Ca 125 ◽

Cytokeratin 19 ◽

Neoplastic Disease ◽

Ca 15.3 ◽

Ca 19.9 ◽

Marcadores Tumorales

Muchos marcadores tumorales (MT) no son específicos a un tipo particular de cáncer y el nivel de uno de ellos puede aumentar como consecuencia de más de un tipo de cáncer, por lo que se utilizan en combinación para lograr mayor efectividad diagnóstica. Este trabajo se propone evaluar el valor diagnóstico de la combinación de nueve MT utilizados en diagnóstico de neoplasia tanto de forma individual como combinados. Se realizó un estudio retrospectivo entre enero 2013 y mayo de 2015 en el Laboratorio Clínico del Centro de Investigaciones Médico Quirúrgicas de La Habana a 100 pacientes con diagnóstico de cáncer o sospecha clínica de neoplasia oculta a quienes se les determinaron los marcadores tumorales: antígeno carbohidrato (CA) 19.9, CA 72.4, CA 125, CA 15.3, antígeno carcinoembrionario (CEA), componente de la citoqueratina 19 (Cyfra 21-1), gonadotropina coriónica (HCG), ferritina y antígeno prostático de superficie (PSA). En todos los MT se observó un incremento del valor de corte sobre el valor límite superior de referencia mayor al 8%. En conjunto, la sensibilidad, especificidad, valor predictivo positivo (VPP) y valor predictivo negativo fueron de 23%, 99%, 96% y 51%, respectivamente. Para un valor de corte de 50 la especificidad y el VPP aumentaron a 99,6% y 97,5%, respectivamente. El uso de los 9 marcadores tumorales en conjunto mostró ser útil en el proceso de diagnóstico de pacientes con enfermedad neoplásica. Palabras clave: marcadores tumorales, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina y PSA Abstract: Many tumor markers are not specific to a particular type of cancer and the level of one of them may increase as a result of more than one type of cancer, that’s why they are used in combination to achieve greater diagnostic effectiveness. This work aims to evaluate the diagnostic value of the combination of nine tumor markers commonly used in diagnosis of neoplasia both individually and in combination. A retrospective study from January 2013 to May 2015 was conducted at the Clinical Laboratory of the Center for Medical and Surgical Research in Havana, in 100 patients with cancer diagnosis or clinical suspicion of occult malignancy and to whom carbohydrate antigen (CA) 19.9, 72.4, CA 125, CA 15.3, carcinoembryonic antigen (CEA), component cytokeratin 19 (CYFRA 21-1), chorionic gonadotropin (HCG), ferritin and prostate surface antigen (PSA) tumor markers were identified. An increase of cutoff value above the upper limit reference value in all higher TM 8% was observed. Overall, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value were 23 %, 99 %, 96 % and 51 %, respectively. For a cut value of 50 specificity and PPV, they increased to 99.6% and 97.5%, respectively. The use of 9 tumor markers together showed to be useful in the process of diagnosing patients with neoplastic disease. Key words: tumor markers, CA 19.9, CA 72.4, CA 125, CA 15.3, CEA, Cyfra 21-1, HCG, Ferritina and PSA.

Download Full-text